Summary of COVID-19 dolutegravir studies

1. Verburgh et al., No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands

2,428 patient dolutegravir prophylaxis study: 14% higher combined mortality/hospitalization (p=0.54) and 20% more cases (p=0.75).
Analysis of two Dutch cohorts with HIV showing no association between tenofovir disoproxil fumarate (TDF), etravirine (ETR), or integrase-strand transfer inhibitors (INSTIs) use and either the risk of incident SARS-CoV-2 infection or severe COVID-19 outcomes.
Apr 2023, AIDS, https://journals.lww.com/10.1097/QAD.0000000000003577, https://c19p.org/verburgh

2. Abbaspour Kasgari et al., Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial

93 patient dolutegravir late treatment RCT: 202% higher mortality (p=0.49) and 5% lower need for oxygen therapy (p=1).
RCT 93 hospitalized patients with moderate COVID-19 showing no significant difference in clinical outcomes with dolutegravir treatment compared to placebo.
Jun 2024, BioImpacts, https://bi.tbzmed.ac.ir/Inpress/bi-29952, https://c19p.org/abbaspourkasgari